Autologous cytokine-induced killer cell therapy in lung cancer patients: A retrospective study

Biomedicine and Pharmacotherapy

Volumn 70, Issue C, 2015, Pages 248-252

  Zhang, Jinying ^a   Zhu, Lingjun ^a   Du, Haina ^a   He, Xiang ^b   Yin, Yongmei ^a   Gu, Yanhong ^a   Liu, Lianke ^a   Lu, Kaihua ^a   Guo, Renhua ^a   Liu, Ping ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical Insurance Billing Management Center   (China)

Author keywords

Cytokine induced killer cells; Immunotherapy; Lung cancer

Indexed keywords

CARBOPLATIN; CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; DOCETAXEL; NAVELBINE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE CONTROL STUDY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; FEMALE; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LUNG CANCER; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; AGED; IMMUNOLOGY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; SURVIVAL RATE; TRANSPLANTATION; TRENDS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84927516392     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.12.025     Document Type: Article

References (28)

1. Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs 2008, 12:587-596.
2. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
3. Patel S., Mehta-Damani A., Shu H., Le Pecq J.B. An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy. Biotechnol Bioeng 2005, 92:238-249.
4. Stroncek D., Berlyne D., Fox B., Gee A., Heimfeld S., Lindblad R., et al. Developments in clinical cell therapy. Cytotherapy 2010, 12:425-428.
5. Shi M., Zhang B., Tang Z.R., Lei Z.Y., Wang H.F., Feng Y.Y., et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004, 10:1146-1151.
6. Schmidt-Wolf I.G., Lefterova P., Johnston V., Huhn D., Blume K.G., Negrin R.S. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994, 87:453-458.
7. Linn Y.C., Lau L.C., Hui K.M. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002, 116:78-86.
8. Linn Y.C., Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003, 44:1457-1462.
9. Zhang Y.S., Yuan F.J., Jia G.F., Zhang J.F., Hu L.Y., Huang L., et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005, 11:3339-3345.
10. Li R., Wang C., Liu L., Du C., Cao S., Yu J., et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012, 61:2125-2133.
11. Mac Manus M.P., Matthews J.P., Wada M., Wirth A., Worotniuk V., Ball D.L. Unexpected long-term survival after low-dose palliative radiotherapy for non-small cell lung cancer. Cancer 2006, 106:1110-1116.
12. Penland S.K., Socinski M.A. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. Semin Radiat Oncol 2004, 14:326-334.
13. Kim H.M., Kang J.S., Lim J., Park S.K., Lee K., Yoon Y.D., et al. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 2007, 30:1464-1470.
14. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
15. Helms M.W., Prescher J.A., Cao Y.A., Schaffert S., Contag C.H. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 2010, 59:1325-1334.
16. Wang Y., Dai H., Li H., Lv H., Wang T., Fu X., et al. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin Dev Immunol 2011, 2011:621414.
17. Yang Z., Zhang Q., Xu K., Shan J., Shen J., Liu L., et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLOS ONE 2012, 7:e44802.
18. Schlimper C., Hombach A.A., Abken H., Schmidt-Wolf I.G. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012, 2012:238924.
19. Baxevanis C.N., Gritzapis A.D., Tsitsilonis O.E., Katsoulas H.L., Papamichail M. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes. Int J Cancer 2002, 98:864-872.
20. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153:1687-1696.
21. Hui K.M. CIK cells - current status, clinical perspectives and future prospects - the good news. Expert Opin Biol Ther 2012, 12:659-661.
22. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002.
23. Hui D., Qiang L., Jian W., Ti Z., Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009, 41:36-41.
24. Zhao H., Fan Y., Li H., Yu J., Liu L., Cao S., et al. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients. Cancer Biother Radiopharm 2013.
25. Sun S., Li X.M., Li X.D., Yang W.S. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm 2005, 20:173-180.
26. + cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 2006, 66:6826-6833.
27. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012, 18:1751-1759.
28. Zhang J., Zhu L., Wei J., Liu L., Yin Y., Gu Y., et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 2012, 138:1057-1062.